Conference Coverage

This channel highlights DAIC's coverage of numerous key cardiology and medical imaging conferences each year. These include ACC, AHA, ASE, ASNC, EuroPCR, ECR, HIMSS, HRS, RSNA, SCAI, SCCT, TCT, and VIVA.

While the HRS annual meeting is cancelled, the society has created a resource page to help its members in the fight against COVID-19 at https://www.hrsonline.org/COVID19-Challenges-Solutions. #HRS #COVID19 #coronavirus #SARScov2

Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

Heart Rhythm Society Cancels 2020 Meeting Due to COVID-19

April 1, 2020 — Due to the continued global escalation of the novel coronavirus (COVID-19, SARS-CoV-2), the Heart Rhythm ...

April 01, 2020

News

E-Cigarettes More Effective Than Counseling for Smoking Cessation

March 30, 2020 — Smokers who received smoking cessation counseling and used electronic cigarettes (e-cigarettes) ...

March 30, 2020

Closing access to the radial artery after harvesting a section of the artery for a coronary artery bypass graft (CABG). Photo by Getty Images. #ACC20 #ACC2020

News | Cardiovascular Surgery

Radial Artery Versus Saphenous Vein For Coronary Bypass Surgery Long Term Follow-up

March 30, 2020 — Patients undergoing coronary bypass graft (CAGB) surgery lived longer and had better outcomes when ...

March 30, 2020

AHA, ACC, HRS, SCAI and other medical societies call for federal government to do what is needed to get medical supplies to front-line clinicians fighting COVID-19. #COVID19 #SARScov2 #Coronavirus

News | Coronavirus (COVID-19)

Healthcare Societies Issue Urgent Call for Federal Action to Address COVID-19 Medical Equipment Shortages

March 30, 2020 — A group of 13 U.S. medical societies sent an open letter to Congress appealing to them to do what is ...

March 30, 2020

Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

News | Heart Valve Technology

TAVR Non-Inferior to Surgery in U.K. Review of Surgery vs. TAVR

March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) did ...

March 30, 2020

PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR

Feature | Heart Valve Technology

TAVR Equivalent to Surgery at Two Years in Low-Risk Patients

March 30, 2020 — Low-risk patients undergoing transcatheter aortic valve repair (TAVR) at two years did just as well ...

March 30, 2020

News | Heart Valve Technology

U.S. TAVR Outcomes Need Improvement Based on TVT Registry Analysis

March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing ...

March 29, 2020

$Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio$

News | Heart Failure

Vericiguat Improves Outcomes in Patients with Worsening Heart Failure

March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational ...

March 29, 2020

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020

Feature | Heart Valve Technology | Dave Fornell, Editor

TAVR Shows Favorable Safety in Patients with Bicuspid Valve

March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve ...

March 29, 2020

POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020

News | Atrial Fibrillation

March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing ...

March 29, 2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

News | Pharmaceuticals | Dave Fornell, Editor

Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials

March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran ...

March 28, 2020

Find more news from ACC 2020.Women carry heavier burden of chest pain, but less artery narrowing according to data in a substudy of the ISCHEMIA Trial. #ACC20 #ACC2020 #ISCHEMIA

News | Womens Cardiovascular Health

Sex Differences in Stress Test and CCTA Findings and Symptoms in the Ischemia Trial

March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia) ...

March 28, 2020

News | Heart Failure

Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis

March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse ...

March 28, 2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

News | Antiplatelet and Anticoagulation Therapies

Antiplatelet Genetic Testing Missed Goal to Cut Cardiovascular Events in Half

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to ...

March 28, 2020

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

News | Peripheral Artery Disease (PAD)

Rivaroxaban Reduces Risks in Peripheral Artery Disease Post-Intervention

March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with ...

March 28, 2020